{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:12Z","timestamp":1787988012689,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Amyloid (A) deposition represents a specific pathological hallmark of Alzheimer\u2019s disease (AD). Clinical diagnostic protocols frequently rely on the combined use of amyloid (A)- and tau (T)- positron emission tomography (PET) imaging to distinguish AD from non-amyloid-associated neurodegenerative conditions. Many neurodegenerative disorders are characterized by distinct tauopathies, which result in different [\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]flortaucipir T-PET topographic patterns. The aim of this study was to investigate, in a memory clinic cohort, whether [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir distribution patterns derived from scaled subprofile modelling using principal component analysis (SSM\/PCA) could differentiate between A\u2009+\u2009and A\u2009\u2212\u2009individuals, potentially eliminating the need for an A-PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 81 subjects were included in this study: 40 with AD characterized by both A and T accumulation (A\u2009+\u2009T\u2009+), 13 with suspected non-Alzheimer\u2019s pathology (A\u2009\u2212\u2009T\u2009+), and 28 without A and T abnormality (A\u2009\u2212\u2009T\u2009\u2212). SSM\/PCA was applied on [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir images to identify two disease patterns (DPs), representing amyloid-positive (A\u2009+\u2009DP) and amyloid-negative (A\u2013 DP) accumulation. Each subject\u2019s imaging data was then compared to these DPs and the resulting similarity scores were used as inputs for three machine learning models \u2013 Support Vector Machine, Random Forest, and Multi-Layer Perceptron \u2013 to predict amyloid status. Finally, Spearman correlation analyses were conducted between SSM\/PCA-derived scores and plasma biomarkers levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The two identified disease patterns exhibited distinct PET signatures consistent with current disease knowledge. Their representativeness was further supported by significant correlations with plasma biomarkers in nearly all cases. All machine learning models confirmed the capacity of the A\u2009+\u2009DP to predict AD pathology, correctly classifying at least 36 out of 40 cases. In contrast, the A\u2009\u2212\u2009DP showed limited discriminative power for non-AD conditions, as indicated by its higher misclassification rate (best performance: 7 correct out of 13).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      SSM\/PCA applied on [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir-PET imaging provide information on both A and T status, supporting its potential use as first and possibly sole examination in the investigation of suspected AD. While for non-AD cases, A-PET scans are still recommended.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07995-z","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:48:10Z","timestamp":1781480890000},"page":"6238-6251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating AD and non-AD [18F]flortaucipir distribution patterns in a memory clinic cohort"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8174-306X","authenticated-orcid":false,"given":"Francesco","family":"Piva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-436X","authenticated-orcid":false,"given":"Cecilia","family":"Boccalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-1753","authenticated-orcid":false,"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-0683","authenticated-orcid":false,"given":"Mattia","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3033-8817","authenticated-orcid":false,"given":"D\u00e9bora Elisa","family":"Peretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"7995_CR1","volume-title":"StatPearls [Internet]","author":"A Kumar","year":"2024","unstructured":"Kumar A, Sidhu J, Lui F, Tsao JW. \u2018Alzheimer disease.\u2019 In: StatPearls [Internet]. StatPearls Publishing; 2024."},{"key":"7995_CR2","doi-asserted-by":"publisher","unstructured":"(2024) \u20182024 Alzheimer\u2019s disease facts and figures\u2019, Alzheimers Dement, 20(5):3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"issue":"4","key":"7995_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"7995_CR4","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49(10):3508\u201328. https:\/\/doi.org\/10.1007\/s00259-022-05784-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7995_CR5","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00259-023-06311-3","volume":"50","author":"DE Peretti","year":"2023","unstructured":"Peretti DE, Ribaldi F, Scheffler M, Chicherio C, Frisoni GB, Garibotto V. Prognostic value of imaging-based ATN profiles in a memory clinic cohort. Eur J Nucl Med Mol Imaging. 2023;50(11):3313\u201323. https:\/\/doi.org\/10.1007\/s00259-023-06311-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7995_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/alz.13355","volume":"20","author":"C Boccalini","year":"2024","unstructured":"Boccalini C, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2024;20(1):221\u201333. https:\/\/doi.org\/10.1002\/alz.13355.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7995_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CJ Jack Jr.","year":"2024","unstructured":"Jack CJ Jr., et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"7995_CR8","doi-asserted-by":"publisher","unstructured":"I. Sonni et al. Evaluation of a visual interpretation method for tau\u2010PET with 18 F\u2010flortaucipir\u2019, Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1). https:\/\/doi.org\/10.1002\/dad2.12133","DOI":"10.1002\/dad2.12133"},{"issue":"8","key":"7995_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334. https:\/\/doi.org\/10.1038\/s41380-018-0342-8.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"7995_CR10","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143(11):3477\u201394. https:\/\/doi.org\/10.1093\/brain\/awaa276.","journal-title":"Brain"},{"key":"7995_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neurobiolaging.2018.02.015","volume":"66","author":"H Cho","year":"2018","unstructured":"Cho H, et al. Predominant subcortical accumulation of 18F-flortaucipir binding in behavioral variant frontotemporal dementia. Neurobiol Aging. 2018;66:112\u201321. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.02.015.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"7995_CR12","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1212\/WNL.0000000000005117","volume":"90","author":"DT Jones","year":"2018","unstructured":"Jones DT, et al. In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology. 2018;90(11):e947-54. https:\/\/doi.org\/10.1212\/WNL.0000000000005117.","journal-title":"Neurology"},{"issue":"1","key":"7995_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/jnnp-2019-320904","volume":"91","author":"RS Convery","year":"2020","unstructured":"Convery RS, et al. Longitudinal (18 F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. J Neurol Neurosurg Psychiatry. 2020;91(1):106\u20138. https:\/\/doi.org\/10.1136\/jnnp-2019-320904.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"7995_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/jnumed.120.244061","volume":"62","author":"J Hammes","year":"2021","unstructured":"Hammes J, et al. One-stop shop: 18 F-Flortaucipir PET differentiates amyloid-positive and -negative forms of neurodegenerative diseases. J Nucl Med. 2021;62(2):240\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.244061.","journal-title":"J Nucl Med"},{"issue":"76","key":"7995_CR15","doi-asserted-by":"publisher","first-page":"50319","DOI":"10.3791\/50319","volume":"76","author":"P Spetsieris","year":"2013","unstructured":"Spetsieris P, et al. \u2018Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp. 2013;76:50319, 50319. https:\/\/doi.org\/10.3791\/50319.","journal-title":"J Vis Exp"},{"issue":"12","key":"7995_CR16","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1177\/0271678X17732508","volume":"37","author":"SK Meles","year":"2017","unstructured":"Meles SK, et al. The Alzheimer\u2019s disease metabolic brain pattern in mild cognitive impairment. J Cereb Blood Flow Metab. 2017;37(12):3643\u20138. https:\/\/doi.org\/10.1177\/0271678X17732508.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7995_CR17","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.nicl.2021.102625","volume":"30","author":"DE Peretti","year":"2021","unstructured":"Peretti DE, et al. Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. Neuroimage Clin. 2021;30:102625, 102625. https:\/\/doi.org\/10.1016\/j.nicl.2021.102625.","journal-title":"Neuroimage Clin"},{"issue":"11","key":"7995_CR18","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144(11):3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"issue":"5","key":"7995_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7995_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"7995_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","journal-title":"Alzheimers Dement"},{"key":"7995_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuroimage.2017.07.050","volume":"161","author":"S Mishra","year":"2017","unstructured":"Mishra S, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage. 2017;161:171\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.07.050.","journal-title":"Neuroimage"},{"issue":"2","key":"7995_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00259-019-04536-9","volume":"47","author":"A Dodich","year":"2020","unstructured":"Dodich A, et al. The A\/T\/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging. 2020;47(2):247\u201355. https:\/\/doi.org\/10.1007\/s00259-019-04536-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"7995_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068910","volume":"8","author":"M Xia","year":"2013","unstructured":"Xia M, Wang J, He Y. BrainNet viewer: a network visualization tool for human brain connectomics. PLoS ONE. 2013;8(7):e68910. https:\/\/doi.org\/10.1371\/journal.pone.0068910.","journal-title":"PLoS ONE"},{"issue":"4","key":"7995_CR25","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.neuroimage.2010.10.025","volume":"54","author":"PG Spetsieris","year":"2011","unstructured":"Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson\u2019s disease: methodological issues. Neuroimage. 2011;54(4):2899\u2013914. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.10.025.","journal-title":"Neuroimage"},{"issue":"1","key":"7995_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135. https:\/\/doi.org\/10.1002\/1097-0142(1950)3:1%3c32::AID-CNCR2820030106%3e3.0.CO;2-3.","journal-title":"Cancer"},{"issue":"6","key":"7995_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363. https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","journal-title":"Nat Med"},{"issue":"4","key":"7995_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","volume":"72","author":"S-Y Wang","year":"2019","unstructured":"Wang S-Y, et al. Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis. 2019;72(4):1353\u201361. https:\/\/doi.org\/10.3233\/JAD-190615.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"7995_CR29","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, et al. Association of glial fibrillary acid protein, Alzheimer\u2019s disease pathology and cognitive decline. Brain. 2024;147(12):4094\u2013104. https:\/\/doi.org\/10.1093\/brain\/awae211.","journal-title":"Brain"},{"issue":"8","key":"7995_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.0000000000003636","volume":"88","author":"S Spina","year":"2017","unstructured":"Spina S, et al. Frontotemporal dementia with the V337M MAPT mutation. Neurology. 2017;88(8):758\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000003636.","journal-title":"Neurology"},{"key":"7995_CR31","doi-asserted-by":"publisher","first-page":"120509","DOI":"10.1016\/j.neuroimage.2024.120509","volume":"286","author":"R Satoh","year":"2024","unstructured":"Satoh R, Ali F, Botha H, Lowe V, Josephs K, Whitwell J. Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy. Neuroimage. 2024;286:120509, 120509. https:\/\/doi.org\/10.1016\/j.neuroimage.2024.120509.","journal-title":"Neuroimage"},{"issue":"6","key":"7995_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2967\/jnumed.121.262685","volume":"63","author":"KA Josephs","year":"2022","unstructured":"Josephs KA, et al. Relationship between 18F-flortaucipir uptake and histologic lesion types in 4-repeat tauopathies. J Nucl Med. 2022;63(6):931\u20135. https:\/\/doi.org\/10.2967\/jnumed.121.262685.","journal-title":"J Nucl Med"},{"issue":"11","key":"7995_CR33","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151\u201362. https:\/\/doi.org\/10.1001\/jama.2018.12917.","journal-title":"JAMA"},{"issue":"6","key":"7995_CR34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2967\/jnumed.121.262685","volume":"63","author":"KA Josephs","year":"2022","unstructured":"Josephs KA, et al. Relationship between 18F-flortaucipir uptake and histologic lesion types in 4-repeat tauopathies. J Nucl Med. 2022;63(6):931\u20135. https:\/\/doi.org\/10.2967\/jnumed.121.262685.","journal-title":"J Nucl Med"},{"issue":"8","key":"7995_CR35","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-021-05301-7","volume":"48","author":"G Ch\u00e9telat","year":"2021","unstructured":"Ch\u00e9telat G, et al. Finding our way through the labyrinth of dementia biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(8):2320\u20134. https:\/\/doi.org\/10.1007\/s00259-021-05301-7.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07995-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:32Z","timestamp":1787986832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7995"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07995-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local Ethics Committee (Cantonal Research Ethics Commission, Geneva, Switzerland) approved the study, which have been conducted under the principles of the Declaration of Helsinki and the Internation Conference on Harmonization Good Clinical Practice. All subject provided written informed consent to have collected data be used in research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each patient or their relatives provided signed informed consent for participation in the study and for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VG received financial support for research and\/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Eli Lilly, Novartis and Roche. G.B.F. has received support, payment, consulting fees or honoraria through his institution for lectures, presentations, speaker bureaus, manuscript writing or educational events from: Biogen, Roche, Diadem, Novo Nordisk, GE Healthcare, OM Pharma and Eisai. H.Z. has served on scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant and on advisory boards for Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programmes for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.Other authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}